US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
KR100850812B1
(ko)
*
|
2000-10-23 |
2008-08-06 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
ME00230B
(me)
|
2002-01-22 |
2011-02-10 |
|
2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni
|
JP4603268B2
(ja)
|
2002-04-19 |
2010-12-22 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
新規化合物
|
US7053088B2
(en)
|
2002-05-22 |
2006-05-30 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
EP1546116A1
(de)
|
2002-08-08 |
2005-06-29 |
Amgen Inc. |
Vanilloidrezeptorliganden und deren verwendung bei behandlungen
|
ES2313016T3
(es)
*
|
2003-07-11 |
2009-03-01 |
Warner-Lambert Company Llc |
Sal de isetionato de un inhibidor selectivo de cdk4.
|
ATE556056T1
(de)
|
2003-07-29 |
2012-05-15 |
Xenon Pharmaceuticals Inc |
Pyridylderivate und deren verwendung als therapeutische mittel
|
NZ545265A
(en)
|
2003-07-30 |
2009-11-27 |
Xenon Pharmaceuticals Inc |
Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
|
EP1663242B1
(de)
*
|
2003-08-07 |
2011-04-27 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
|
EP1670794A2
(de)
|
2003-09-30 |
2006-06-21 |
Amgen Inc. |
Vanilloidrezeptorliganden und deren verwendung bei behandlungen
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
AU2005212438A1
(en)
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
JP2007530654A
(ja)
*
|
2004-03-30 |
2007-11-01 |
ファイザー・プロダクツ・インク |
シグナル伝達阻害剤の組合せ
|
EP1742634B1
(de)
*
|
2004-04-13 |
2010-10-27 |
ICAgen, Inc. |
Polycyclische pyrimidine als kaliumionenkanal-modulatoren
|
US7335672B2
(en)
|
2004-09-13 |
2008-02-26 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
BRPI0515500A
(pt)
|
2004-09-20 |
2008-07-29 |
Xenon Pharmaceuticals Inc |
derivados piridazina para inibição de estearoil-coa-desaturase
|
US7592343B2
(en)
|
2004-09-20 |
2009-09-22 |
Xenon Pharmaceuticals Inc. |
Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
|
CN101083982A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
|
EP1799664A1
(de)
|
2004-09-20 |
2007-06-27 |
Xenon Pharmaceuticals Inc. |
Heterozyklische derivate und ihre verwendung als stearoyl-coa-desaturase-inhibitoren
|
EP2266569A3
(de)
|
2004-09-20 |
2011-03-09 |
Xenon Pharmaceuticals Inc. |
Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
|
BRPI0515488A
(pt)
|
2004-09-20 |
2008-07-29 |
Xenon Pharmaceuticals Inc |
derivados de heterocìclicos e seu uso como agentes terapêuticos
|
AR051091A1
(es)
|
2004-09-20 |
2006-12-20 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
US7314933B2
(en)
|
2004-10-22 |
2008-01-01 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CN101048410B
(zh)
|
2004-10-29 |
2010-06-23 |
泰博特克药品有限公司 |
抑制hiv的双环嘧啶衍生物
|
AU2006205851A1
(en)
|
2005-01-14 |
2006-07-20 |
Janssen Pharmaceutica N.V. |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
US7947694B2
(en)
|
2005-01-14 |
2011-05-24 |
Janssen Pharmaceutica Nv |
Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors
|
US7301022B2
(en)
|
2005-02-15 |
2007-11-27 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
PE20100741A1
(es)
*
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
US7423042B2
(en)
*
|
2005-03-25 |
2008-09-09 |
Glaxo Group Limited |
Compounds
|
CN101495475A
(zh)
*
|
2005-03-25 |
2009-07-29 |
葛兰素集团有限公司 |
制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
|
MX2007015216A
(es)
|
2005-06-03 |
2008-02-22 |
Xenon Pharmaceuticals Inc |
Derivados de aminotiazol y sus usos como agentes terapeuticos.
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
RU2452737C2
(ru)
*
|
2006-03-30 |
2012-06-10 |
Тиботек Фармасьютикалз Лтд. |
5-(гидроксиметилен- и аминометилен)замещенные пиримидины, ингибирующие вич
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
PE20080695A1
(es)
*
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
WO2007125405A2
(en)
*
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
JP2009545592A
(ja)
*
|
2006-07-31 |
2009-12-24 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
コード化小分子ライブラリーからのオーロラキナーゼ阻害剤
|
JP2009545598A
(ja)
|
2006-08-01 |
2009-12-24 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
P38キナーゼ阻害剤
|
US7981893B2
(en)
|
2006-10-19 |
2011-07-19 |
Signal Pharmaceuticals, Llc |
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
|
CN101611035A
(zh)
*
|
2006-12-28 |
2009-12-23 |
大正制药株式会社 |
吡唑并嘧啶化合物
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
JP2010525047A
(ja)
*
|
2007-04-27 |
2010-07-22 |
アストラゼネカ アクチボラグ |
増殖状態の処置のためのEphB4キナーゼ阻害剤としてのN’−(フェニル)−N−(モルホリン−4−イル−ピリジン−2−イル)−ピリミジン−2,4−ジアミン誘導体
|
WO2008148889A1
(en)
|
2007-06-08 |
2008-12-11 |
Bayer Cropscience Sa |
Fungicide heterocyclyl-pyrimidinyl-amino derivatives
|
US8461147B2
(en)
*
|
2007-12-03 |
2013-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
NZ586069A
(en)
|
2007-12-19 |
2012-05-25 |
Amgen Inc |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
MX2010010975A
(es)
|
2008-04-07 |
2010-11-01 |
Amgen Inc |
Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
|
AU2009257602B2
(en)
|
2008-06-10 |
2015-10-08 |
Abbvie Inc. |
Novel tricyclic compounds
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
BRPI0917791B1
(pt)
*
|
2008-08-22 |
2022-03-22 |
Novartis Ag |
Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
EA021367B1
(ru)
*
|
2008-11-28 |
2015-06-30 |
Кова Компани, Лтд. |
Производное пиридин-3-карбоксамида
|
JP2012514020A
(ja)
|
2008-12-29 |
2012-06-21 |
フォーヴィア・ファーマシューティカルズ |
置換キナゾリン化合物
|
PE20120110A1
(es)
|
2009-02-13 |
2012-02-20 |
Fovea Pharmaceuticals |
[1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
|
AU2010232727A1
(en)
|
2009-03-31 |
2011-10-20 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
AU2010248886A1
(en)
|
2009-05-13 |
2011-12-01 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
BRPI1010882A2
(pt)
*
|
2009-06-08 |
2019-09-24 |
California Capital Equity Llc |
derivados de triazina e suas aplicações terapêuticas.
|
WO2010144647A1
(en)
|
2009-06-12 |
2010-12-16 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
EP3091021B1
(de)
|
2009-10-26 |
2019-08-28 |
Signal Pharmaceuticals, LLC |
Verfahren zur synthese und reinigung von heteroarylverbindungen
|
ME02800B
(de)
|
2009-12-01 |
2018-01-20 |
Abbvie Inc |
Neue trizyklische verbindungen
|
SG181147A1
(en)
|
2009-12-01 |
2012-07-30 |
Abbott Lab |
Novel tricyclic compounds
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
US8637529B2
(en)
|
2010-06-11 |
2014-01-28 |
AbbYie Inc. |
Pyrazolo[3,4-d]pyrimidine compounds
|
AR081960A1
(es)
|
2010-06-22 |
2012-10-31 |
Fovea Pharmaceuticals Sa |
Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
|
KR20200137048A
(ko)
|
2010-10-25 |
2020-12-08 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
JP2013545758A
(ja)
|
2010-11-17 |
2013-12-26 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
増殖性キナーゼcdk4及びcdk6の阻害による虚血からの腎組織の保護
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
WO2012080284A2
(en)
|
2010-12-17 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
MY161199A
(en)
|
2011-03-23 |
2017-04-14 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
LT2699553T
(lt)
|
2011-04-22 |
2024-02-12 |
Signal Pharmaceuticals, Llc |
Pakeistas diaminokarboksamidas ir diaminokarbonitrilo pirimidinai, jų kompozicijos ir gydymo būdai
|
US9493466B2
(en)
|
2011-10-19 |
2016-11-15 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with TOR kinase inhibitors
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
CN104093398B
(zh)
|
2011-12-02 |
2017-03-15 |
西格诺药品有限公司 |
7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法
|
EP2802577B1
(de)
*
|
2012-01-13 |
2017-03-01 |
Bristol-Myers Squibb Company |
Triazolylsubstituierte pyridylverbindungen als kinaseinhibitoren
|
WO2013106641A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
JP6109195B2
(ja)
*
|
2012-01-13 |
2017-04-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
キナーゼ阻害剤として有用な複素環置換されたピリジル化合物
|
TWI615143B
(zh)
|
2012-02-24 |
2018-02-21 |
標誌製藥公司 |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
EP3216792B1
(de)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactamkinaseinhibitoren
|
CN106008511B
(zh)
*
|
2012-05-14 |
2018-08-14 |
华东理工大学 |
蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
WO2014007951A2
(en)
|
2012-06-13 |
2014-01-09 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
JP2015532281A
(ja)
*
|
2012-09-26 |
2015-11-09 |
マンカインド コーポレイション |
複数キナーゼ経路阻害剤
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
EP2922840B1
(de)
*
|
2012-11-08 |
2016-12-21 |
Bristol-Myers Squibb Company |
Bicyclische heterocyclische substituierte pyridinverbindungen als kinasemodulatoren
|
TW201427953A
(zh)
|
2012-11-08 |
2014-07-16 |
必治妥美雅史谷比公司 |
可作爲激酶調節劑之經雜芳基取代的吡啶化合物
|
CN104968664A
(zh)
*
|
2012-12-12 |
2015-10-07 |
山东亨利医药科技有限责任公司 |
作为酪氨酸激酶抑制剂的并环化合物
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
KR20150108389A
(ko)
|
2013-01-16 |
2015-09-25 |
시그날 파마소티칼 엘엘씨 |
치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법
|
WO2014144847A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
WO2014139145A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Hutchison Medipharma Limited |
Novel pyrimidine and pyridine compounds and usage thereof
|
CN107417691B
(zh)
|
2013-03-15 |
2020-06-26 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
US9474757B2
(en)
|
2013-04-17 |
2016-10-25 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
WO2014172431A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
BR112015026021A2
(pt)
|
2013-04-17 |
2017-07-25 |
Signal Pharm Llc |
terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
|
MX2015014590A
(es)
|
2013-04-17 |
2016-03-03 |
Signal Pharm Llc |
Tratamiento de cancer con dihidropirazino-pirazinas.
|
JP6382948B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
|
CN111166751A
(zh)
|
2013-04-17 |
2020-05-19 |
西格诺药品有限公司 |
化合物的药物制剂、程序、固体形式和使用方法
|
CN105473142A
(zh)
|
2013-04-17 |
2016-04-06 |
西格诺药品有限公司 |
用二氢吡嗪并-吡嗪治疗癌症
|
KR102469849B1
(ko)
|
2013-04-19 |
2022-11-23 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
CN113831345A
(zh)
|
2013-05-29 |
2021-12-24 |
西格诺药品有限公司 |
二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
|
JP6483707B2
(ja)
|
2013-12-20 |
2019-03-13 |
シグナル ファーマシューティカルズ,エルエルシー |
置換されたジアミノピリミジル化合物、それらの組成物、及びそれらによる治療方法
|
UY35935A
(es)
|
2014-01-03 |
2015-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
|
JP2017504628A
(ja)
*
|
2014-01-31 |
2017-02-09 |
小野薬品工業株式会社 |
縮合イミダゾール化合物
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
JP6752715B2
(ja)
|
2014-03-26 |
2020-09-09 |
アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited |
組合せ
|
CN106456648B
(zh)
|
2014-03-26 |
2021-11-02 |
阿斯特克斯治疗有限公司 |
Fgfr抑制剂和igf1r抑制剂的组合
|
EP3131551A4
(de)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
Feste formen mit 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-on und co-former, zusammensetzungen und verfahren zu deren verwendung
|
WO2015160882A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
ES2823756T3
(es)
|
2014-04-16 |
2021-05-10 |
Signal Pharm Llc |
Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
WO2015161287A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of normal cells during chemotherapy
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
US9623028B2
(en)
|
2014-07-14 |
2017-04-18 |
Signal Pharmaceuticals, Llc |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
US9828373B2
(en)
|
2014-07-26 |
2017-11-28 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
CN104496983B
(zh)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
CN104447743B
(zh)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
EA038045B1
(ru)
|
2015-02-20 |
2021-06-28 |
Инсайт Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
CN106146515B
(zh)
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
CN110078741B
(zh)
*
|
2015-04-24 |
2021-10-01 |
广州再极医药科技有限公司 |
稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
|
CN106279173A
(zh)
*
|
2015-05-29 |
2017-01-04 |
华东理工大学 |
蝶啶酮衍生物作为egfr抑制剂的应用
|
AR105113A1
(es)
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
UY36747A
(es)
|
2015-06-24 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
|
CN109641906B
(zh)
|
2015-06-24 |
2021-10-01 |
百时美施贵宝公司 |
杂芳基取代的氨基吡啶化合物
|
AU2016297784B2
(en)
|
2015-07-24 |
2020-12-24 |
Celgene Corporation |
Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
|
RU2747644C2
(ru)
|
2015-09-23 |
2021-05-11 |
Янссен Фармацевтика Нв |
Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака
|
EP3353177B1
(de)
|
2015-09-23 |
2020-06-03 |
Janssen Pharmaceutica NV |
Trizyklische heterozyklen zur behandlung von krebs
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
SG10201913987UA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
NZ749275A
(en)
*
|
2016-07-01 |
2023-06-30 |
G1 Therapeutics Inc |
Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
|
MX2019000200A
(es)
|
2016-07-01 |
2019-09-26 |
G1 Therapeutics Inc |
Agentes antiproliferativos basados en pirimidina.
|
JP6745905B2
(ja)
*
|
2016-11-28 |
2020-08-26 |
帝人ファーマ株式会社 |
ピリド[3,4−d]ピリミジン誘導体又はその溶媒和物の結晶
|
EA201991622A1
(ru)
|
2017-01-06 |
2020-01-23 |
Г1 Терапьютикс, Инк. |
Комплексная терапия для лечения рака
|
CA3062602A1
(en)
|
2017-05-11 |
2018-11-15 |
Bristol-Myers Squibb Company |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
TWI787284B
(zh)
|
2017-06-22 |
2022-12-21 |
美商西建公司 |
以b型肝炎病毒感染表徵之肝細胞癌之治療
|
RU2019142591A
(ru)
|
2017-06-29 |
2021-07-29 |
Г1 Терапьютикс, Инк. |
Морфологические формы g1t38 и способы их получения
|
CN107759596A
(zh)
*
|
2017-12-05 |
2018-03-06 |
安庆奇创药业有限公司 |
一种合成帕博西尼的方法
|
CN108299312B
(zh)
*
|
2018-03-29 |
2020-10-30 |
郑州大学第一附属医院 |
一组嘧啶类衍生物及其在制备抗肿瘤药物中的应用
|
MX2020011718A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
|
PE20210919A1
(es)
|
2018-05-04 |
2021-05-19 |
Incyte Corp |
Sales de un inhibidor de fgfr
|
CN112839657A
(zh)
|
2018-08-24 |
2021-05-25 |
G1治疗公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
WO2021062327A1
(en)
*
|
2019-09-27 |
2021-04-01 |
Jubilant Biosys Limited |
Fused pyrimidine compounds, compositions and medicinal applications thereof
|
IL291901A
(en)
|
2019-10-14 |
2022-06-01 |
Incyte Corp |
Bicyclyl heterocycles as fgr suppressors
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
JP2023505257A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤の誘導体
|
EP4069696A1
(de)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclische heterocyclen als fgfr-inhibitoren
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN115551856A
(zh)
*
|
2020-02-28 |
2022-12-30 |
重庆复尚源创医药技术有限公司 |
作为cdk2/4/6抑制剂的化合物
|
IL297714A
(en)
*
|
2020-04-28 |
2022-12-01 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and their uses
|
MX2022014573A
(es)
|
2020-05-19 |
2022-12-15 |
G1 Therapeutics Inc |
Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos.
|
CN113801118A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的蝶啶酮衍生物及其应用
|
CN113801139A
(zh)
*
|
2020-06-12 |
2021-12-17 |
华东理工大学 |
作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
CN113087708A
(zh)
*
|
2021-04-06 |
2021-07-09 |
南方医科大学 |
一种蝶啶酮类化合物及其应用
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Fgfr阻害剤としての三環式ヘテロ環
|
TW202317106A
(zh)
|
2021-08-27 |
2023-05-01 |
南韓商柳韓洋行 |
作為egfr抑制劑之取代胺基吡啶化合物
|
TW202328096A
(zh)
|
2021-08-27 |
2023-07-16 |
南韓商柳韓洋行 |
作為egfr抑制劑之含五員雜芳基之胺基吡啶化合物
|
WO2023143135A1
(zh)
*
|
2022-01-28 |
2023-08-03 |
赛诺哈勃药业(成都)有限公司 |
一种喹唑啉衍生物及其用途
|
US20240092761A1
(en)
*
|
2022-07-18 |
2024-03-21 |
Iambic Therapeutics, Inc. |
Quinazoline compounds and methods of use
|